sirt in 2

SIRT-IN-2 is a potent SIRT1 2 3 inhibitor [IC50s of 4, 1, and 7 μM, respectively].

Sirt2-IN-1 is an inhibitor of sirtuin 2 (IC50 = 163 nM).

Sirt1 2-IN-2 (compound hsa55) is a dual inhibitor, targeting SIRT1 with an IC50 of 1.8 μM and SIRT2 with an IC50 of 2.4 μM. It effectively inhibits p53 deacetylation while enhancing the acetylation of p53 and α-tubulin, promoting apoptosis and exhibiting anti-proliferative effects on human leukemia cell lines [1].

Sirt1/2-IN-4 (compound PS3) is a potent triple inhibitor of SIRT1, SIRT2, and SIRT3, exhibiting IC50 values of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respectively. It effectively inhibits p53 deacetylation, indicating potential anticancer properties [1].

SIRT1 2 3-IN-1 (compound 10) is a potent, selective, and cell-permeable inhibitor targeting SIRT1, SIRT2, and SIRT3, with inhibitory concentrations (IC50s) of 0.54 μM, 0.253 μM, and 0.72 μM, respectively. It is utilized in cancer research [1].

**SIRT2-IN-14 (Compound 78)** is a selective SIRT2 inhibitor, demonstrating an IC50 value of 0.196 μM [1].

SIRT5 inhibitor 2 (compound 49) is a potent SIRT5 inhibitor (IC50 = 2.3 μM) that shows inhibitory activity against SIRT5-dependent desuccinylation and has research value in cancer and neurodegenerative diseases.

HSP70/SIRT2-IN-1 (Compound 2a) serves as a dual inhibitor targeting both SIRT2 and HSP70, exhibiting an IC50 of 17.3±2.0 μM against SIRT2. This compound possesses antitumor activity [1].

SIRT1-A2 is a SIRT1 activator.

Sirt1 2-IN-3 (compound PS9) serves as a dual inhibitor of SIRT1 2, exhibiting IC50 values of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respectively. This compound effectively inhibits p53 deacetylation while simultaneously elevating p53 and α-tubulin acetylation levels. Additionally, Sirt1 2-IN-3 promotes apoptosis and exhibits antiproliferative effects on human leukemia cell lines [1].

HSP70 SIRT2-IN-2 (Compounds 1a), a dual inhibitor of SIRT2 and HSP70, exhibits an IC50 of 45.1±5.0 μM against SIRT2 and demonstrates antitumor activity [1].

SIRT2-IN-11 (AEM1) is a selective inhibitor of SIRT2 with an inhibitory concentration (IC50) of 18.5 μM. It induces apoptosis in a p53-dependent manner, activates the expression of CDKN1A, PUMA, and NOXA, and enhances the acetylation of p53. This compound is utilized in the study of p53-associated cancers.

SIRT2-IN-10 (Compound 12) is a potent SIRT2 inhibitor (IC50: 1.3 μM) useful for cancer and neurodegenerative disease research.

SIRT1/2 Inhibitor IV (cannabinol) is a small-molecule inhibitor of SIRT1 and SIRT2 with IC50 values of 56 μM and 59 μM, respectively.

Sirt2-IN-7 (compound 22), a selective SIRT2 inhibitor with an IC50 of 178.2 nM and a Ki of 154.3 nM, is employed in cancer research [1].

PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC that acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1 Sirt3 (IC50s > 100 μM)[1].

SIRT2-IN-9 is a selective SRIT2 inhibitor with an IC50 value of 1.3 μM.SIRT2-IN-9 inhibits the proliferation of MCF-7 breast cancer cells.SIRT2-IN-9 can be used for cancer research.

Sirt2-IN-6 is a potent and selective inhibitor of SIRT2 (IC50: 0.815 μM) and can be used to study cancer.

Sirt1 2-IN-1 (Compound 7) is an inhibitor of SIRT1 and SIRT2, with IC50 values of 1.81 μg mL for SIRT1, 2.10 μg mL for SIRT2, and 20.5 μg mL for SIRT3, and exhibits α-microtubulin hyperacetylation activity, demonstrating significant anticancer effects.

Sirt2-IN-5, a potent inhibitor of SIRT2, is specifically (2S)-2-[(Z)-4-(3-chlorophenyl)-3-methylbutanoylamino]-5-methylhexanoic acid [exact (1:1) of (2S,4R)-4-[(Z)-4-(3-chlorophenyl)-3-methylbutanoylamino]-5-methylhexanoic acid].

SIRT1-IN-2 (compound 3h) is a potent and selective inhibitor of SIRT1 (silent information regulator 1) with an IC50 of 1.6 μM [1].

SIRT-IN-1 is a potent inhibitor of SIRT1, SIRT2, and SIRT3, with IC50 values of 15, 10, and 33 μM, respectively

Decapeptide-12, a competitive inhibitor of mushroom tyrosinase with an IC50 of 40 µM and a Kd of 61.1 μM for the C-terminal residue of tyrosinase, is a small oligopeptide that reduces melanin content in melanocytes by interacting with tyrosinase and increasing transcription of SIRT. It is utilized in researching melanogenesis, senescence, and inflammation [1] [2] [3].

SIRT-IN-3, a potent inhibitor of SIRT1 with an IC50 value of 17 μM, exhibits approximate 4-fold and 14-fold greater selectivity for SIRT1 over SIRT2 and SIRT3, with respective IC50 values of 74 μM for SIRT2 and 235 μM for SIRT3 [1].